.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,294,199

« Back to Dashboard

Details for Patent: 6,294,199

Title: Method of treating a bacterial infection comprising administering amoxycillin
Abstract:Bacterial infections may be treated using a high dosage regimen of amoxycillin. Preferably, the dosage is provided by a bilayer tablet.
Inventor(s): Conley; Creighton P. (Bristol, TN), Roush; John A. (Kingsport, TN), Storm; Kevin H. (Bristol, TN)
Assignee: Beecham Pharmaceuticals (Pte) Limited (Singapore, SG)
Filing Date:Apr 06, 2000
Application Number:09/544,417
Claims:1. A method of treating a bacterial infection in a human in need thereof which method comprises administering to said human a dosage of a therepeutically effective amount of amoxycillin in the range of 1900 to 2600 mg, at a dosage regimen interval of about 12 h, and wherein the infection is caused by the organism S pneumoniae (including Drug Resistant and Penicillin Resistant S pneumoniae), H influenzae, M catarrhalis and/or S pyogenes.

2. The method according to claim 1 in which the dosage regimen provides a mean plasma concentration of amoxycillin of 4 .mu.g/mL for at least 4.4 h and a mean maximum plasma concentration (C.sub.max) of amoxycillin of at least 12 .mu.g/mL.

3. The method according to claim 1 in which the dosage regimen provides a mean plasma concentration of amoxycillin of 4 .mu.g/mL for at least 4.8 h and a mean maximum plasma concentration (C.sub.max) of amoxycillin of at least 16 .mu.g/mL.

4. The method according to claim 1 in which the dosage regimen provides a mean plasma concentration of amoxycillin of 8 .mu.g/mL for at least 4.4 h.

5. The method according to claim 1 in which the dosage is delivered from an immediate release formulation.

6. The method according to claim 5 in which the dosage is 2000, 2250 or 2500 mg of amoxycillin.

7. The method according to claim 6 in which the dosage is provided as a single tablet, or as a number of smaller tablets, may be the same or different.

8. The method according to claim 1 in which the dosage is delivered from a modified release formulation.

9. The method according to claim 8 in which the dosage is provided as a number of tablets, which may be the same or different.

10. The method according to claim 8 in which the dosage is 2000, 2250 or 2500 mg of amoxycillin.

11. A method of treating a bacterial infection in a human in need thereof which method comprises administering to said human a dosage of a therapeutically effective amount of amoxycillin in the range of 1400 to 1900 mg, at dosage regimen interval of about 12 h, such that the dosage regimen provides a mean plasma concentration of amoxycillin of 4 1.mu.g/mL for at least 4.4 h, and a mean maximum plasma concentration (Cmax) of amoxycillin of at least 12 .mu.g/mL.

12. The method according to claim 11 in which the dosage regimen provides a mean plasma concentration of amoxycillin of 4 .mu.g/ml for at least 4.8 h and a mean maximum plasma concentration (Cmax) of amoxycillin of at least 16 .mu.g/ml.

13. The method according to claim 11 in which the dosage is delivered from a modified release formulation.

14. The method according to claim 11 in which the dosage is 1500 or 1750 mg of amoxycillin.

15. The method according to claim 11 in which the infection is caused by the organisms S pneumoniae (including Drug Resistant and Penicillin Resistant S pneumoniae), H influenzae, M catarrhalis and/or S pyogenes.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc